Therapeutic cancer vaccines: past, present, and future.
Therapeutic cancer vaccines: past, present, and future.
复制标题
DOI：
10.1016/b978-0-12-407190-2.00007-1
复制
发表时间：
2013
影响因子：
--
通讯作者：
Wang, Xiang-Yang
中科院分区：
文献类型：
--
作者：
Guo, Chunqing;Manjili, Masoud H.;Subjeck, John R.;Sarkar, Devanand;Fisher, Paul B.;Wang, Xiang-Yang
治疗性疫苗是癌症主动免疫疗法的一种可行选择，旨在通过使用患者自己的免疫系统来治疗晚期疾病。最近，临床试验令人振奋的结果导致美国食品和药物管理局批准了第一种治疗性癌症疫苗。这一重大突破不仅为癌症管理提供了一种新的治疗模式，而且为合理设计和优化未来具有更高抗癌效果的疫苗铺平了道路。许多疫苗策略目前正在临床前和临床上进行评估。本文综述了不同平台或靶点的治疗性肿瘤疫苗，以及使用这些治疗性疫苗的临床前和临床研究。我们还将考虑阻碍治疗性疫苗效力的肿瘤诱导的免疫抑制，以及产生更强大和更持久的抗肿瘤免疫反应的潜在策略。
Therapeutic vaccines represent a viable option for active immunotherapy of cancers that aim to treat late stage disease by using a patient's own immune system. The promising results from clinical trials recently led to the approval of the first therapeutic cancer vaccine by the U.S. Food and Drug Administration. This major breakthrough not only provides a new treatment modality for cancer management, but also paves the way for rationally designing and optimizing future vaccines with improved anticancer efficacy. Numerous vaccine strategies are currently being evaluated both pre-clinically and clinically. This review discusses therapeutic cancer vaccines of diverse platforms or targets as well as the preclinical and clinical studies employing these therapeutic vaccines. We will also consider tumor-induced immune suppression that hinders the potency of therapeutic vaccines, and potential strategies to counteract these mechanisms for generating more robust and durable antitumor immune responses.